Processa Pharmaceuticals, Inc.
PCSA
$2.44
-$0.01-0.41%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.61M | 4.92M | 4.77M | 4.78M | 4.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.02M | 12.96M | 12.09M | 12.05M | 11.79M |
| Operating Income | -13.02M | -12.96M | -12.09M | -12.05M | -11.79M |
| Income Before Tax | -12.93M | -12.88M | -11.96M | -11.85M | -11.53M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.93 | -12.88 | -11.96 | -11.85 | -11.53 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.93M | -12.88M | -11.96M | -11.85M | -11.53M |
| EBIT | -13.02M | -12.96M | -12.09M | -12.05M | -11.79M |
| EBITDA | -13.02M | -12.96M | -12.09M | -12.05M | -11.79M |
| EPS Basic | -35.00 | -59.02 | -77.93 | -98.13 | -121.38 |
| Normalized Basic EPS | -21.87 | -36.89 | -48.71 | -61.33 | -75.86 |
| EPS Diluted | -35.00 | -59.02 | -77.93 | -98.13 | -121.38 |
| Normalized Diluted EPS | -21.87 | -36.89 | -48.71 | -61.33 | -75.86 |
| Average Basic Shares Outstanding | 3.05M | 1.28M | 771.80K | 489.40K | 405.30K |
| Average Diluted Shares Outstanding | 3.05M | 1.28M | 771.80K | 489.40K | 405.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |